JBIO
Jade Biosciences Inc
NASDAQ · Biotechnology
$15.32
+0.93 (+6.46%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 85.08M | 76.59M | 82.32M |
| Net Income | 21.83M | 19.00M | 17.76M |
| EPS | — | — | — |
| Profit Margin | 25.7% | 24.8% | 21.6% |
| Rev Growth | +15.3% | +2.7% | +8.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 76.69M | 69.48M | 73.29M |
| Total Equity | 434.50M | 430.53M | 489.70M |
| D/E Ratio | 0.18 | 0.16 | 0.15 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 33.39M | 28.41M | 32.89M |
| Free Cash Flow | 16.91M | 11.51M | 18.65M |